Quarterly report · Q2
4543.TEDINET S100S9UJ
Period2023-04-01 → 2023-09-30
Filed2023-11-14
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 61
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥443.9bn | 2023-04-01 → 2023-09-30 | Cons. | Revenue IFRS |
| Revenue | ¥228.6bn | 2023-07-01 → 2023-09-30d | Cons. | Revenue IFRS |
| Revenue | ¥820.2bn | 2022-04-01 → 2023-03-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥403.3bn | 2022-04-01 → 2022-09-30 | Cons. | Revenue IFRS |
| Revenue | ¥206.0bn | 2022-07-01 → 2022-09-30d | Cons. | Revenue IFRS |
| Operating income | ¥66.5bn | 2023-04-01 → 2023-09-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥36.8bn | 2023-07-01 → 2023-09-30d | Cons. | Operating profit loss IFRS |
| Operating income | ¥56.0bn | 2022-04-01 → 2022-09-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥25.5bn | 2022-07-01 → 2022-09-30d | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥66.4bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥36.6bn | 2023-07-01 → 2023-09-30d | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥116.1bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥54.6bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥25.0bn | 2022-07-01 → 2022-09-30d | Cons. | Profit loss before tax IFRS |
| Net income (owners) | ¥50.1bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥27.5bn | 2023-07-01 → 2023-09-30d | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥89.3bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥40.3bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥17.9bn | 2022-07-01 → 2022-09-30d | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | ¥50.1bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss IFRS |
| Net income | ¥27.5bn | 2023-07-01 → 2023-09-30d | Cons. | Profit loss IFRS |
| Net income | ¥40.3bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss IFRS |
| Net income | ¥17.9bn | 2022-07-01 → 2022-09-30d | Cons. | Profit loss IFRS |
| Total assets | ¥1.75T | at 2023-09-30 | Cons. | Assets IFRS |
| Total assets | ¥1.60T | at 2023-03-31 | Cons. | Assets IFRS |
| Total assets | ¥1.66T | at 2022-09-30 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥487.4bn | at 2023-09-30 | Cons. | Liabilities IFRS |
| Total liabilities | ¥491.2bn | at 2023-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥1.26T | at 2023-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.11T | at 2023-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.17T | at 2022-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.01T | at 2022-03-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥1.26T | at 2023-09-30 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥1.11T | at 2023-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥1.17T | at 2022-09-30 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥187.3bn | at 2023-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥187.3bn | at 2023-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥212.6bn | at 2022-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥205.3bn | at 2022-03-31d | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | ¥53.6bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥117.5bn | 2022-04-01 → 2023-03-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥60.3bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥36.1bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥59.1bn | 2022-04-01 → 2023-03-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥31.6bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | −¥30.0bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥86.6bn | 2022-04-01 → 2023-03-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥37.9bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥67.27 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥36.99 | 2023-07-01 → 2023-09-30d | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥119 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥53.37 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥23.75 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥67.24 | 2023-04-01 → 2023-09-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥36.97 | 2023-07-01 → 2023-09-30d | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥118.95 | 2022-04-01 → 2023-03-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥53.35 | 2022-04-01 → 2022-09-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥23.74 | 2022-07-01 → 2022-09-30d | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 72.1% | at 2023-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 69.3% | at 2023-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 70.6% | at 2022-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 20
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue external | 2023-04-01 → 2023-09-30 | ¥119m |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-09-30 | −¥1.0bn |
| jpcrp040300-q2r_E01630-000Blood And Cell Technologies Companyreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥84.1bn |
| jpcrp040300-q2r_E01630-000Blood And Cell Technologies Companyreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥10.6bn |
| jpcrp040300-q2r_E01630-000Cardiac And Vascular Companyreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥265.7bn |
| jpcrp040300-q2r_E01630-000Cardiac And Vascular Companyreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥57.6bn |
| jpcrp040300-q2r_E01630-000Medical Care Solutions Companyreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥94.0bn |
| jpcrp040300-q2r_E01630-000Medical Care Solutions Companyreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥8.3bn |
| —segment total | revenue external | 2023-04-01 → 2023-09-30 | ¥443.8bn |
| —segment total | segment profit | 2023-04-01 → 2023-09-30 | ¥76.6bn |
| Reconciling Itemsreconciling | revenue external | 2022-04-01 → 2022-09-30 | ¥124m |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-09-30 | ¥275m |
| jpcrp040300-q2r_E01630-000Blood And Cell Technologies Companyreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥74.0bn |
| jpcrp040300-q2r_E01630-000Blood And Cell Technologies Companyreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥9.1bn |
| jpcrp040300-q2r_E01630-000Cardiac And Vascular Companyreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥235.4bn |
| jpcrp040300-q2r_E01630-000Cardiac And Vascular Companyreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥52.9bn |
| jpcrp040300-q2r_E01630-000Medical Care Solutions Companyreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥93.8bn |
| jpcrp040300-q2r_E01630-000Medical Care Solutions Companyreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥8.1bn |
| —segment total | revenue external | 2022-04-01 → 2022-09-30 | ¥403.2bn |
| —segment total | segment profit | 2022-04-01 → 2022-09-30 | ¥70.2bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 690
| Item | Context | Value | Unit |
|---|---|---|---|
| Depreciation and amortization ope cf IFRS | Prior1YTDDuration | 34357000000 | JPY |
| Depreciation and amortization ope cf IFRS | CurrentYTDDuration | 36788000000 | JPY |
| Impairment losses reversal of impairment losses ope cf IFRS | Prior1YTDDuration | 5280000000 | JPY |
| Impairment losses reversal of impairment losses ope cf IFRS | CurrentYTDDuration | － | JPY |
| Share of loss profit of investments accounted for using equity method ope cf IFRS | Prior1YTDDuration | 303000000 | JPY |
| Share of loss profit of investments accounted for using equity method ope cf IFRS | CurrentYTDDuration | -100000000 | JPY |
| Increase or decrease in retirement benefit asset or liability ope cf IFRS | Prior1YTDDuration | -430000000 | JPY |
| Increase or decrease in retirement benefit asset or liability ope cf IFRS | CurrentYTDDuration | -729000000 | JPY |
| Interest and dividend income ope cf IFRS | Prior1YTDDuration | -532000000 | JPY |
| Interest and dividend income ope cf IFRS | CurrentYTDDuration | -1042000000 | JPY |
| Interest expenses ope cf IFRS | Prior1YTDDuration | 1308000000 | JPY |
| Interest expenses ope cf IFRS | CurrentYTDDuration | 724000000 | JPY |
| Foreign exchange loss gain ope cf IFRS | Prior1YTDDuration | 3749000000 | JPY |
| Foreign exchange loss gain ope cf IFRS | CurrentYTDDuration | 1226000000 | JPY |
| Loss gain on sale and retirement of fixed assets ope cf IFRS | Prior1YTDDuration | -192000000 | JPY |
| Loss gain on sale and retirement of fixed assets ope cf IFRS | CurrentYTDDuration | -159000000 | JPY |
| Gain on sales of subsidiaries and affiliates stocks ope cf IFRS | Prior1YTDDuration | － | JPY |
| Gain on sales of subsidiaries and affiliates stocks ope cf IFRS | CurrentYTDDuration | -1335000000 | JPY |
| Decrease increase in trade and other receivables ope cf IFRS | Prior1YTDDuration | 2465000000 | JPY |
| Decrease increase in trade and other receivables ope cf IFRS | CurrentYTDDuration | -7166000000 | JPY |
| Decrease increase in inventories ope cf IFRS | Prior1YTDDuration | -13328000000 | JPY |
| Decrease increase in inventories ope cf IFRS | CurrentYTDDuration | -6939000000 | JPY |
| Increase decrease in trade and other payables ope cf IFRS | Prior1YTDDuration | -1451000000 | JPY |
| Increase decrease in trade and other payables ope cf IFRS | CurrentYTDDuration | -7764000000 | JPY |
| Other changes in working capital ope cf IFRS | Prior1YTDDuration | -12262000000 | JPY |
| Other changes in working capital ope cf IFRS | CurrentYTDDuration | -5024000000 | JPY |
| Subtotal ope cf IFRS | Prior1YTDDuration | 73893000000 | JPY |
| Subtotal ope cf IFRS | CurrentYTDDuration | 74904000000 | JPY |
| Interest and dividends received ope cf IFRS | Prior1YTDDuration | 1200000000 | JPY |
| Interest and dividends received ope cf IFRS | CurrentYTDDuration | 1872000000 | JPY |
| Interest paid ope cf IFRS | Prior1YTDDuration | -766000000 | JPY |
| Interest paid ope cf IFRS | CurrentYTDDuration | -555000000 | JPY |
| Income taxes refund paid ope cf IFRS | Prior1YTDDuration | -13980000000 | JPY |
| Income taxes refund paid ope cf IFRS | CurrentYTDDuration | -22641000000 | JPY |
| Net cash provided by used in operating activities IFRS | Prior1YTDDuration | 60346000000 | JPY |
| Net cash provided by used in operating activities IFRS | CurrentYTDDuration | 53579000000 | JPY |
| Payments into time deposits inv cf IFRS | Prior1YTDDuration | -175000000 | JPY |
| Payments into time deposits inv cf IFRS | CurrentYTDDuration | -789000000 | JPY |
| Proceeds from withdrawal of time deposits inv cf IFRS | Prior1YTDDuration | 0 | JPY |
| Proceeds from withdrawal of time deposits inv cf IFRS | CurrentYTDDuration | － | JPY |
| Purchase of property plant and equipment inv cf IFRS | Prior1YTDDuration | -24631000000 | JPY |
| Purchase of property plant and equipment inv cf IFRS | CurrentYTDDuration | -28175000000 | JPY |
| Proceeds from sale of property plant and equipment inv cf IFRS | Prior1YTDDuration | 430000000 | JPY |
| Proceeds from sale of property plant and equipment inv cf IFRS | CurrentYTDDuration | 667000000 | JPY |
| Purchase of intangible assets inv cf IFRS | Prior1YTDDuration | -9940000000 | JPY |
| Purchase of intangible assets inv cf IFRS | CurrentYTDDuration | -9676000000 | JPY |
| Purchase of marketable securities inv cf IFRS | Prior1YTDDuration | -601000000 | JPY |
| Purchase of marketable securities inv cf IFRS | CurrentYTDDuration | -930000000 | JPY |
| Proceeds from sale of marketable securities inv cf IFRS | Prior1YTDDuration | 3444000000 | JPY |
| Proceeds from sale of marketable securities inv cf IFRS | CurrentYTDDuration | － | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 16 of 16 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |